I have no idea sorry - but assume Jarden are not privy to any more info than the rest of us (maybe a nudge and wink somewhere though?)
Printable View
Thanks Pierre, makes one wonder what we miss out on...
Otago has bugger all say anymore. They are a very minor shareholder.
As for biotech buy outs, a general rule of thumb is 4-5x gross turnover. That would be 4.5B by 2030 numbers...........LOL thats not going to happen.
I would anticipate somewhere around 500M for this asset which means PE need to be turning over 130-150M (150,000-160,000 tests p.a.).....within 2-3yrs to justify the patent runout time